Press release 📈 Stocks 🌍 United States

Eloxx Pharmaceuticals Publishes Phase 2a Exaluren Data for Alport Syndrome

Eloxx Pharmaceuticals reports positive Phase 2a proof-of-mechanism data for exaluren in Alport syndrome, showing improved kidney cell structure in three patients, with Phase 2b topline results expected in mid-2027.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: ELOX ↑ 4/10 (60% confidence).

📊 Affected Assets (1)

ELOX
Bullish 🤖 60%
📅 Short-term 🌍 US · Explicit

The Journal of Clinical Investigation publication provides first-in-human proof of mechanism for exaluren: increased collagen IV abundance and partially improved podocyte morphology in all three participants, with no serious adverse events, supporting the ongoing Phase 2b EXACT study. However, the study had only three patients, was open-label, proteinuria changes were inconsistent and hematuria persisted, so the outlook shift is modest rather than decisive.

Catalysts
  • ▲ Publication of Phase 2a proof-of-mechanism data in the Journal of Clinical Investigation on Nov. 18, 2026
  • ▲ Phase 2b EXACT trial dosing underway since September 2026
Risk Factors
  • ▼ Only three patients in an open-label study, which the company itself notes is not necessarily predictive of future results
  • ▼ Changes in proteinuria were inconsistent and hematuria persisted in all participants

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Phase 2a study of three patients showed increased collagen IV abundance and improved podocyte morphology after eight weeks of treatment.
  • Exaluren was well tolerated with no serious adverse events, nephrotoxicity, or ototoxicity reported in the study.
  • The ongoing Phase 2b EXACT trial, which began dosing in September 2026, expects 16-week topline data in mid-2027.
  • Exploratory analysis indicated a 50% increase in mean filtration slit density across all three participants.

📝 Executive Summary

Eloxx Pharmaceuticals announced the publication of Phase 2a study results for exaluren in the Journal of Clinical Investigation. The study of three patients demonstrated increased collagen IV abundance and improved podocyte morphology, supporting the ongoing Phase 2b EXACT trial. While the drug was well tolerated with no serious adverse events, clinical measures like proteinuria remained inconsistent.

❓ FAQ

Is this new clinical trial result or just a journal article?

It is the peer-reviewed publication of results from the already-completed Phase 2a study of exaluren in three patients aged 12 to 18, showing increased collagen IV in kidney biopsies and no serious adverse events; the larger Phase 2b EXACT trial is still ongoing.

When will the next major data readout be?

The company expects topline data from the 16-week placebo-controlled portion of the Phase 2b EXACT study in mid-2027, with 32-week data by the end of 2027.